Agomab Therapeutics NV - AGMB

Ownership (Schedule 13D / 13G) · latest 50 filings · Back to all files
Visible: 0
Filed Form Reporting person Percent Shares SEC
May 15, 2026 SCHEDULE 13G Redmile Group, LLC 5.6% 2,735,926 View
May 15, 2026 SCHEDULE 13G Jeremy C. Green 5.6% 2,735,926 View
May 15, 2026 SCHEDULE 13G Redmile Biopharma Investments III, L.P. 5.6% 2,735,926 View
May 15, 2026 SCHEDULE 13G Cormorant Asset Management, LP 5.01% 2,465,348 View
May 15, 2026 SCHEDULE 13G Bihua Chen 5.01% 2,465,348 View
Apr 16, 2026 SCHEDULE 13G Pontifax VI G.P. L.P. 6.8% 3,305,846 View
Apr 16, 2026 SCHEDULE 13G Pontifax Management 4 G.P. (2015) Ltd. 6.8% 3,305,846 View
Apr 16, 2026 SCHEDULE 13G Ran Nussbaum 6.8% 3,305,846 View
Apr 16, 2026 SCHEDULE 13G Tomer Kariv 6.8% 3,305,846 View
Mar 06, 2026 SCHEDULE 13G FMR LLC 10.0% 4,873,680 View
Mar 06, 2026 SCHEDULE 13G Abigail P. Johnson 10.0% 4,873,680 View
Feb 17, 2026 SCHEDULE 13D 10.6% View
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G. Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F). Amendments (/A) can repeat the same holder over time, so rows should not be summed. Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.